A. Vasilev, R. Sofi, R. Rahman, S. J. Smith, A. G. Teschemacher, S. Kasparov. Using light for therapy of glioblastoma multiforme (GBM). Brain Sci 2020; 10(2): 75.

M. W. Yu, D. F. Quail. Immunotherapy for glioblastoma: current progress and challenges. Front Immunol 2021; 12: 676301.

B. Yuan, G. Wang, X. Tang, A. Tong, L. Zhou. Immunotherapy of glioblastoma: recent advances and future prospects. Hum Vaccin Immunother 2022; 18(5): 2055417.

Q. Wang, Y. Qin, B. Li. CD8+ T cell exhaustion and cancer immunotherapy. Cancer Lett 2023; 559: 216043.

V. S. Arnesen, A. Gras Navarro, M. Chekenya. Challenges and prospects for designer T and NK cells in glioblastoma immunotherapy. Cancers (Basel) 2021; 13(19): 4986.

H. Wang, H. Zhou, J. Xu, Y. Lu, X. Ji, Y. Yao. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy. Cancer Lett 2021; 496: 134-143.

J. A. Belk, B. Daniel, A. T. Satpathy. Epigenetic regulation of T cell exhaustion. Nat Immunol 2022; 23(6): 848-860.

J. Lee, M. Nicosia, E. S. Hong, D. J. Silver, C. Li, D. Bayik. Sex-biased T-cell exhaustion drives differential immune responses in glioblastoma. Cancer Discov 2023; 13(9): 2090-2105.

D. Chen, M. Wang, Y. Guo, W. Wu, X. Ji, X. Dou. An aberrant DNA methylation signature for predicting the prognosis of head and neck squamous cell carcinoma. Cancer Med 2021; 10(17): 5936-5947.

S. Wang, Y. Xiong, L. Zhao, K. Gu, Y. Li, F. Zhao. UCSCXenaShiny: an R/CRAN package for interactive analysis of UCSC Xena data. Bioinformatics 2022; 38(2): 527-529.

C. Pizzimenti, V. Fiorentino, M. Franchina, M. Martini, G. Giuffrè, M. Lentini. Autophagic-Related Proteins in Brain Gliomas: Role, Mechanisms, and Targeting Agents. Cancers (Basel) 2023; 15(9): 2622.

J. H. Sampson, M. D. Gunn, P. E. Fecci, D. M. Ashley. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 2020; 20(1): 12-25.

Z. Zhang, L. Chen, H. Chen, J. Zhao, K. Li, J. Sun. Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy. EBioMedicine 2022; 83: 104207.

N. D. Mathewson, O. Ashenberg, I. Tirosh, S. Gritsch, E. M. Perez, S. Marx. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell 2021; 184(5): 1281-1298.e26.

M. C. Garrett, R. Albano, T. Carnwath, L. Elahi, C. A. Behrmann, M. Pemberton. HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma. Sci Rep 2023; 13(1): 12433.

P. Y. Wen, R. J. Packer. The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. Neuro Oncol 2021; 23(8): 1215-1217.

N. H. Boyd, A. N. Tran, J. D. Bernstock, T. Etminan, A. B. Jones, G. Y. Gillespie. Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics 2021; 11(2): 665-683.

B. L. McClellan, S. Haase, F. J. Nunez, M. S. Alghamri, A. A. Dabaja, P. R. Lowenstein. Impact of epigenetic reprogramming on antitumor immune responses in glioma. J Clin Invest 2023; 133(2): 2.

U. Shahzad, M. Nikolopoulos, C. Li, M. Johnston, J. J. Wang, N. Sabha. CASCADES, a novel SOX2 super-enhancer-associated long noncoding RNA, regulates cancer stem cell specification and differentiation in glioblastoma. Mol Oncol 2025; 19(3): 764-784.

J. D. Bernstock, S. E. Gary, N. Klinger, P. A. Valdes, W. Ibn Essayed, H. E. Olsen. Standard clinical approaches and emerging modalities for glioblastoma imaging. Neurooncol Adv 2022; 4(1): vdac080.

P. Y. Wen, A. Stein, M. van den Bent, J. De Greve, A. Wick, F. Y. de Vos. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol 2022; 23(1): 53-64.

A. M. Sonabend, A. Gould, C. Amidei, R. Ward, K. A. Schmidt, D. Y. Zhang. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol 2023; 24(5): 509-522.

C. McNamara, K. Mankad, S. Thust, L. Dixon, C. Limback-Stanic, F. D’Arco. 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. Neuroradiology 2022; 64(10): 1919-1950.

C. Nayak, S. K. Singh. Integrated Transcriptome Profiling Identifies Prognostic Hub Genes as Therapeutic Targets of Glioblastoma: Evidenced by Bioinformatics Analysis. ACS Omega 2022; 7(26): 22531-22550.

H. Wu, C. Guo, C. Wang, J. Xu, S. Zheng, J. Duan. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma. Cancer Sci 2023; 114(6): 2609-2621.

H. L. Smith, N. Wadhwani, C. Horbinski. Major Features of the 2021 WHO Classification of CNS Tumors. Neurotherapeutics 2022; 19(6): 1691-1704.

A. G. Osborn, D. N. Louis, T. Y. Poussaint, L. L. Linscott, K. L. Salzman. The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know. AJNR Am J Neuroradiol 2022; 43(7): 928-937.

F. Amirmahani, S. Kumar, S. D. Muthukrishnan. Epigenetic mechanisms of plasticity and resistance in glioblastoma: therapeutic targets and implications. Front Epigenet Epigenom 2025; 3: 1519449.

G. Bedics, P. Szőke, B. Bátai, T. Nagy, G. Papp, N. Kránitz. Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas. Sci Rep 2023; 13(1): 18436.

L. Zhang, S. Fritah, P. V. Nazarov, T. Kaoma, E. Van Dyck. Impact of IDH Mutations, the 1p/19q Co-Deletion and the G-CIMP Status on Alternative Splicing in Diffuse Gliomas. Int J Mol Sci 2023; 24(12): 9825.

A. Shahani, H. Slika, A. Elbeltagy, A. Lee, C. Peters, T. Dotson. The epigenetic mechanisms involved in the treatment resistance of glioblastoma. Cancer Drug Resist 2025; 8: 12.

M. S. Uddin, A. A. Mamun, B. S. Alghamdi, D. Tewari, P. Jeandet, M. S. Sarwar. Epigenetics of glioblastoma multiforme: from molecular mechanisms to therapeutic approaches. Semin Cancer Biol 2022; 83: 100-120.

J. Zhao, X. Cui, Q. Zhan, K. Zhang, D. Su, S. Yang. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma. Theranostics 2024; 14(7): 2835-2855.

K. Mitchell, S. A. Sprowls, S. Arora, S. Shakya, D. J. Silver, C. M. Goins. WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma. Genes Dev 2023; 37(3-4): 86-102.

P. Sharma, J. P. Allison. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol 2020; 20(2): 75-76.

S. K. Paidi, J. Rodriguez Troncoso, P. Raj, P. Monterroso Diaz, J. D. Ivers, D. E. Lee. Raman spectroscopy and machine learning reveal early tumor microenvironmental changes induced by immunotherapy. Cancer Res 2021; 81(22): 5745-5755.

B. Tołpa, J. Depciuch, P. Jakubczyk, W. Paja, K. Pancerz, A. Wosiak. Fourier transform infrared spectroscopic marker of glioblastoma obtained from machine learning and changes in the spectra. Photodiagnosis Photodyn Ther 2023; 42: 103550.

H. J. Nam, Y. E. Kim, B. S. Moon, H. Y. Kim, D. Jung, S. Choi. Azathioprine antagonizes aberrantly elevated lipid metabolism and induces apoptosis in glioblastoma. iScience 2021; 24(3): 102238.

X. Wu, F. Geng, X. Cheng, Q. Guo, Y. Zhong, T. F. Cloughesy. Lipid Droplets Maintain Energy Homeostasis and Glioblastoma Growth via Autophagic Release of Stored Fatty Acids. iScience 2020; 23(10): 101569.

J. Du, Y. Su, C. Qian, D. Yuan, K. Miao, D. Lee. Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells. Nat Commun 2020; 11(1): 4830.

H. J. Lee, Z. Chen, M. Collard, F. Chen, J. G. Chen, M. Wu. Multimodal Metabolic Imaging Reveals Pigment Reduction and Lipid Accumulation in Metastatic Melanoma. BME Front 2021; : 9860123.

D. N. Louis, A. Perry, P. Wesseling, D. J. Brat, I. A. Cree, D. Figarella-Branger. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23(8): 1231-1251.

C. M. Chang, K. K. Ramesh, V. Huang, S. Gurbani, L. R. Kleinberg, B. D. Weinberg. Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat. Tomography 2023; 9(3): 942-954.

Y. Nakagawa-Saito, S. Saitoh, Y. Mitobe, A. Sugai, K. Togashi, S. Suzuki. HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny. Int J Mol Sci 2022; 23(15): 8084.

T. Yu, F. Zhou, W. Tian, R. Xu, B. Wang, A. Zeng. EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma. Oncogene 2023; 42(6): 461-470.

F. Pang, L. Zhang, M. Li, X. Yi, Y. Wang, P. Yang. Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma. Cancer Gene Ther 2023; 30(12): 1636-1648.

P. Laskowska, A. Borek-Dorosz, A. M. Nowakowska, E. Kurtz, M. Szydłowski, P. Juszczyński.